Baker M A, Falk J A, Carter W H, Taub R N
N Engl J Med. 1979 Dec 20;301(25):1353-7. doi: 10.1056/NEJM197912203012501.
We tested serial bone-marrow samples from 47 adults with acute myeloblastic leukemia in remission for reactivity with heteroantiserums to leukemia-associated antigens, to determine whether imminent relapse could be detected in patients with acute leukemia. Of 26 patients who relapsed by standard morphologic criteria, 21 had increased immunoreactivity of bone marrow for one to six months (mean, 3.7 months) before relapse. High concordance was observed between a positive test and relapse during the period of study (chi-square = 27.53, P less than 0.001). The median time to relapse after a positive test was four months, as compared with the median remission duration of 19 months for the whole group (P less than 0.02, Peto's log-rank analysis). Serologic detection of leukemia-associated antigens in marrow may be a reliable indicator of imminent relapse in acute myeloblastic leukemia.
我们检测了47例处于缓解期的急性髓细胞白血病成年患者的系列骨髓样本与白血病相关抗原异种抗血清的反应性，以确定急性白血病患者是否能检测到即将复发。在26例按标准形态学标准复发的患者中，21例在复发前1至6个月（平均3.7个月）骨髓免疫反应性增加。在研究期间，检测阳性与复发之间观察到高度一致性（卡方=27.53，P<0.001）。检测阳性后复发的中位时间为4个月，而整个组的中位缓解期为19个月（P<0.02，Peto对数秩分析）。骨髓中白血病相关抗原的血清学检测可能是急性髓细胞白血病即将复发的可靠指标。
